Table 1 Series of ⩾15 patients with MPM treated with single-agent chemotherapy since 1995
From: Chemotherapy for malignant pleural mesothelioma: past results and recent developments
Responders | ||||||
|---|---|---|---|---|---|---|
Single agent | First author (year) | No. of patients | No | % | 95% confidence interval (%) | Median survival (months) |
Anthracyclines and related compounds | ||||||
Liposomal doxorubicin | 32 | 2 | 6 | 0–20 | 13 | |
Liposomal doxorubicin | 24 | 0 | 0 | na | 9.3 | |
Liposomal danaurubicin | Steele (1998) | 11 | 0 | 0 | na | 6.1 |
Platinum compounds | ||||||
ZD0473 | 10 | Two regressions of evaluable disease | na | na | ||
Alkylating agents | ||||||
Ifosfamide | 26 | 1 | 4 | 0–11 | 10 | |
Etoposide i.v. | 49 | 2 | 4 | 1–15 | 7.3 | |
Etoposide p.o. | 45 | 3 | 7 | 2–20 | 9.5 | |
Topoisomerase interactive agents | ||||||
Campthotecin analogues | ||||||
Irinotecan | 28 | 0 | 0 | 10–55 | 7.9 | |
Topotecan | ||||||
22 | 0 | 0 | na | 8 | ||
Antimicrotubule agents | ||||||
Vinca alcaloids | ||||||
Vinorelbine | 64 | 12 | 21 | 10–44 | 13.4 | |
Vincristine | 23 | 0 | 0 | 0–14 | 7 | |
Vinblastine | 20 | 0 | 0 | 0–16 | 3 | |
Taxanes | ||||||
Docetaxel | 19 | 1 | 5 | 0–26 | na | |
Docetaxel | 22 | 3 | 14 | 7–46 | 12 | |
Paclitaxel | v. Meerbeck (1996) | 25 | 0 | 0 | 0–15 | 9.8 |
Paclitaxel | 35 | Three regressions of evaluable disease | 2–10 | 5 | ||
Antimetabolites | ||||||
Edatrexate | 20 | 5 | 25 | 9–49 | 9.6 | |
Edatrexate+LV-rescue | 38 | 6 | 16 | 6–31 | 6.6 | |
Gemcitabine | 17 | 0 | 0 | 3–13 | 4.1 | |
Gemcitabine | 27 | 2 | 7 | 1–24 | 8 | |
Gemcitabine | 16 | 5 | 31 | na | na | |
Pemetrexed | 62 | 9 | 6 | na | 10.7 | |
